HOME >> BIOLOGY >> NEWS
Two-pronged attack targeting EGF receptor hinders cancer cell growth

Hitting the epidermal growth factor receptor (EGFR) both high and low with a combination of drugs for targeted cancer therapy curbs cancer cell growth more effectively than using the drugs each by themselves, researchers from the University of Wisconsin-Madison reported in the August 1 issue of the journal Cancer Research.

EGFR drives unregulated growth in many types of cancer, and the new molecular cancer drugs, cetuximab (Erbitux, ImClone), and gefitinib (Iressa, AstraZeneca) have recently gained FDA approval as therapeutics targeted at the EGFR to inhibit cancer cell proliferation. A third EGFR inhibiting drug, and erlotinib (Tarceva, Genentech), may have FDA approval within a year.

The Wisconsin study examined the combined effect of Erbitux with either Iressa or Tarceva to control growth of head and neck, prostate, and lung cancer cell lines grown in culture, and lung cancer tumors developing in animals.

Tandem application of either Erbitux and Iressa, or Erbitux and Tarceva, proved synergistically more effective than single drug treaent at several levels.

"The combination of Erbitux with either Iressa or Tarceva inhibited cancer cell growth both in cell culture and in live animals more effectively than any of the drugs alone," said the study's senior author, Paul Harari, M.D., associate professor of human oncology, University of Wisconsin Medical School and Comprehensive Cancer Center.

"The impact of these drugs in combination exceeded the effect each had on controlling the growth, cellular signaling, and tumor development when administered alone," added Shyhmin Huang, Ph.D., a senior scientist in Harari's laboratory and lead author on the publication.

The anti-EGFR drugs are of two types:

  • The monoclonal antibody Erbitux hits the EGFR high, binding to a specific site on the receptor outside the cell membrane. Erbitux blocks the receptor from responding to extracellular signals that tu
    '"/>


Contact: Russell Vanderboom, PhD
vanderboom@aacr.org
215-440-9300
American Association for Cancer Research
1-Aug-2004


Page: 1 2 3

Related biology news :

1. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
2. Smart gene therapy protects against damage from heart attack
3. Reading hexametric rhyme supports cardiac synchronization, especially after a heart attack
4. New standard to help diagnose heart attacks
5. Variation of gene associated with decreased risk of heart attack and stroke
6. Dampened hopes for transplanting bone marrow stem cells in heart attacks
7. Protein may help prevent autoimmune attacks
8. Biosensor-regulated gene therapy reduces heart attack damage in mice
9. Lion attacks on livestock in Africa are significant but manageable
10. New approach limits damage after heart attack and improves survival, say Scripps Research scientists
11. Stem-cell therapy could have benefits and risks for heart-attack PTs

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/2/2017)... Australian stem cell and regenerative medicine company, ... an agreement with the Monash Lung Biology Network, a ... and Department of Pharmacology at Monash University, ... to support the use of Cymerus™ mesenchymal stem cells ... Asthma is a chronic, long term lung condition recognised ...
(Date:2/28/2017)... LOS ANGELES , Feb. 28, 2017   ... identity verification software globally, announces significant enhancements to new ... in May 2016. New products include mobile and desktop ... and DocX TM - a real time manual ... Acuant,s core idScan® technology provides the fastest and most ...
(Date:2/28/2017)... Februar 2017  EyeLock LLC, ein marktführendes Unternehmen im ... biometrische Lösung zur Iris-Erkennung auf der neuesten ... auf dem Mobile World Congress 2017 (27. ... Halle 3, Stand 3E10, vorstellen. ... Haven™ – eine Kombination aus Hardware, Software ...
Breaking Biology News(10 mins):
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... at a Marketing Roundtable on March 22 in Philadelphia. The event was offered ... , The Marketing Roundtable featured breakout groups and interaction with speakers ...
(Date:3/28/2017)... LONDON , March 28, 2017 ... to better understand Enzo Biochem and its partnering interests and ... since 2010 report provides an in-depth insight into the partnering ... On demand company reports are prepared upon purchase ... and company data. The report will be delivered ...
(Date:3/28/2017)... , March 28, 2017  The National Pharmaceutical ... joined the health policy research organization as its newest ... and Regulatory Affairs ( North America ), ... of Directors. "We,re pleased to have Ipsen ... President Dan Leonard . "We welcome their insights ...
(Date:3/28/2017)... , March 28, 2017 Biostage, ... biotechnology company developing bioengineered organ implants to treat cancers ... trachea, today announced that Jim McGorry, CEO ... and BioEngineering panel at the MassBio 2017 ... 2:30 PM ET in Cambrige, Massachussetts. The 3D ...
Breaking Biology Technology:
Cached News: